BIO-TECHNE Enters Definitive Merger Agreement with Merck KGaA at $73/Share
TECH sits 65% above its 52-week low of $43.195 on elevated volume (15× avg).
Summary
BIO-TECHNE Corp has signed a definitive merger agreement to be acquired by Merck KGaA for $73.00 per share in cash, a premium over its current stock price.
Key Events · M&A and Partnerships · TECH
-
Definitive Merger Agreement
BIO-TECHNE will be acquired by Merck KGaA for $73.00 per share in an all-cash transaction, as detailed in the Agreement and Plan of Merger dated June 25, 2026.
-
Shareholder and Regulatory Approvals
The merger is subject to customary closing conditions, including approval by BIO-TECHNE shareholders and various antitrust and investment screening regulatory clearances.
-
Termination Fees Established
The agreement includes a Company Termination Fee of $230,455,000 and a Parent Termination Fee of $576,140,000, reflecting the significant commitment of both parties.
-
Executive Retention Bonuses Approved
Cash retention bonuses totaling $6,704,860 were approved for named executive officers to encourage their continued performance through the merger process.
Analysis · TECH · Life Sciences
BIO-TECHNE Corporation has entered into a definitive agreement to be acquired by Merck KGaA for $73.00 per share in an all-cash transaction. This formalizes the acquisition terms, including significant termination fees and executive retention bonuses, following the initial announcement. The offer price represents a premium over the current trading price and is near the company's 52-week high, indicating a favorable outcome for shareholders.
At the time of this filing, TECH was trading at $71.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $43.20 to $72.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.